Income Statement
FIBROBIOLOGICS, INC.
FBLG
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY |
|---|---|---|---|
|
Revenue
|
- | - | - |
|
Cost of Revenue
|
- | - | - |
|
Gross Profit
|
- | - | - |
|
Operating Expenses
|
16.65 | 13.74 | 8.89 |
|
Research & Development
|
7.41 | 4.50 | 2.37 |
|
Selling, General & Administrative
|
9.24 | 9.23 | 6.52 |
|
Other Operating Expenses
|
- | - | - |
|
Operating Income
|
-16.65 | -13.74 | -8.89 |
|
Non-Operating Income
|
-2.00 | - | -0.21 |
|
Interest Income
|
0.25 | 0.25 | - |
|
Interest Expense
|
0.20 | 0.02 | 0.15 |
|
Other Non-Op Income / Expense
|
-0.62 | 0.03 | - |
|
Income Before Tax
|
- | - | - |
|
Income Tax Expense
|
- | - | - |
|
Non-Controlling Interest
|
- | - | - |
|
Net Income
|
-18.65 | 5.21 | 23.72 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY |
|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - |
|
EBITDA
|
-16.65 | -13.74 | -8.89 |
|
Earnings Per Share (Basic)
|
-0.42 | -0.34 | -0.68 |
|
Diluted EPS
|
-0.42 | -0.34 | -0.68 |
|
Weighted Average Shares
|
44.66 | 32.88 | 28.23 |
|
Diluted Weighted Avg Shares
|
44.66 | 32.88 | 28.23 |
|
Comprehensive Income
|
- | - | - |